Sorrento Therapeutics subsidiary updates pipeline progress
Sorrento Therapeutics subsidiary TNK Therapeutics has provided an update on its lead chimeric antigen receptor expressing T cells programs for the treatment of hematological malignancies. Sorrento intends to present these findings at upcoming clinical conferences and in scientific publications. The anti-CD38 CAR-T program is in development for the treatment of multiple myeloma. TNK has developed a proprietary second generation anti-CD38 CAR based on a fully human anti-CD38 monoclonal antibody derived from Sorrento's G-MAB antibody library. CD38-expressing multiple myeloma tumor cells were killed efficiently in vitro, and the CD38 CAR-T cells completely eradicated tumors in a xenograft mouse model of human multiple myeloma. The anti-CD123 CAR-T program is in development for the treatment of acute myeloid leukemia. IND Filings are planned for H1 2017, with initiation of Phase 1 clinical studies expected in H2 2017.